Phenotypic characterization and anti-tumor effects of cytokine-induced killer cells derived from cord blood

Zhen Zhang, Xianlan Zhao, Tengfei Zhang, Liping Wang, Lingzhu Yang, Lan Huang, Feng Li, Jinyan Liu, Dongli Yue, Fei Wang, Jieyao Li, Fangxia Guan, Yuming Xu, Bin Zhang, Yi Zhang

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background aims: Cytokine-induced killer (CIK) cell therapy represents a feasible immunotherapeutic option for treating malignancies. However, the number of anti-tumor lymphocytes cannot be easily obtained from the cancer patients with poor immunity status, and older patients cannot tolerate repeated collection of blood. Cord blood-derived CIK (CB-CIK) cells have shown efficacy in treating the patients with cancer in several clinical trials. This study was conducted to evaluate the biological characteristics and anti-tumor function of CB-CIK cells. Methods: The immunogenicity, chemokine receptors and proliferation of CB-CIK cells were analyzed by flow cytometry. The CIK cells on day 13 were treated with cisplatin and the anti-apoptosis capacity was analyzed. The function of CB-CIK cells against the human cancer was evaluated both in vitro and in vivo. Results: Compared with peripheral blood-derived CIK (PB-CIK) cells, CB-CIK cells demonstrated lower immunogenicity and increased proliferation rates. CB-CIK cells also had a higher percentage of main functional fraction CD3+CD56+. The anti-apoptosis ability of CB-CIK cells after treatment with cisplatin was higher than that of PB-CIK cells. Furthermore, CB-CIK cells were effective for secreting interleukin-2 and interferon-γ and a higher percentage of chemokine receptors CCR6 and CCR7. In addition, tumor growth was greatly inhibited by CB-CIK treatment in a nude mouse xenograft model. Conclusions: CB-CIK cells exhibit more efficient anti-tumor activity in in vitro analysis and in the preclinical model and may serve as a potential therapeutic approach for the treatment of cancer.

Original languageEnglish (US)
Pages (from-to)86-97
Number of pages12
JournalCytotherapy
Volume17
Issue number1
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Cytokine-Induced Killer Cells
Fetal Blood
Neoplasms
Chemokine Receptors
Cisplatin
Apoptosis
Therapeutics
Cell- and Tissue-Based Therapy

Keywords

  • Cancer
  • Cord blood
  • Cytokine-induced killer cells
  • Peripheral blood

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Genetics(clinical)
  • Cell Biology
  • Cancer Research
  • Transplantation

Cite this

Phenotypic characterization and anti-tumor effects of cytokine-induced killer cells derived from cord blood. / Zhang, Zhen; Zhao, Xianlan; Zhang, Tengfei; Wang, Liping; Yang, Lingzhu; Huang, Lan; Li, Feng; Liu, Jinyan; Yue, Dongli; Wang, Fei; Li, Jieyao; Guan, Fangxia; Xu, Yuming; Zhang, Bin; Zhang, Yi.

In: Cytotherapy, Vol. 17, No. 1, 01.01.2015, p. 86-97.

Research output: Contribution to journalArticle

Zhang, Z, Zhao, X, Zhang, T, Wang, L, Yang, L, Huang, L, Li, F, Liu, J, Yue, D, Wang, F, Li, J, Guan, F, Xu, Y, Zhang, B & Zhang, Y 2015, 'Phenotypic characterization and anti-tumor effects of cytokine-induced killer cells derived from cord blood', Cytotherapy, vol. 17, no. 1, pp. 86-97. https://doi.org/10.1016/j.jcyt.2014.09.006
Zhang, Zhen ; Zhao, Xianlan ; Zhang, Tengfei ; Wang, Liping ; Yang, Lingzhu ; Huang, Lan ; Li, Feng ; Liu, Jinyan ; Yue, Dongli ; Wang, Fei ; Li, Jieyao ; Guan, Fangxia ; Xu, Yuming ; Zhang, Bin ; Zhang, Yi. / Phenotypic characterization and anti-tumor effects of cytokine-induced killer cells derived from cord blood. In: Cytotherapy. 2015 ; Vol. 17, No. 1. pp. 86-97.
@article{075bd5ee6440487e875f49ba2b184788,
title = "Phenotypic characterization and anti-tumor effects of cytokine-induced killer cells derived from cord blood",
abstract = "Background aims: Cytokine-induced killer (CIK) cell therapy represents a feasible immunotherapeutic option for treating malignancies. However, the number of anti-tumor lymphocytes cannot be easily obtained from the cancer patients with poor immunity status, and older patients cannot tolerate repeated collection of blood. Cord blood-derived CIK (CB-CIK) cells have shown efficacy in treating the patients with cancer in several clinical trials. This study was conducted to evaluate the biological characteristics and anti-tumor function of CB-CIK cells. Methods: The immunogenicity, chemokine receptors and proliferation of CB-CIK cells were analyzed by flow cytometry. The CIK cells on day 13 were treated with cisplatin and the anti-apoptosis capacity was analyzed. The function of CB-CIK cells against the human cancer was evaluated both in vitro and in vivo. Results: Compared with peripheral blood-derived CIK (PB-CIK) cells, CB-CIK cells demonstrated lower immunogenicity and increased proliferation rates. CB-CIK cells also had a higher percentage of main functional fraction CD3+CD56+. The anti-apoptosis ability of CB-CIK cells after treatment with cisplatin was higher than that of PB-CIK cells. Furthermore, CB-CIK cells were effective for secreting interleukin-2 and interferon-γ and a higher percentage of chemokine receptors CCR6 and CCR7. In addition, tumor growth was greatly inhibited by CB-CIK treatment in a nude mouse xenograft model. Conclusions: CB-CIK cells exhibit more efficient anti-tumor activity in in vitro analysis and in the preclinical model and may serve as a potential therapeutic approach for the treatment of cancer.",
keywords = "Cancer, Cord blood, Cytokine-induced killer cells, Peripheral blood",
author = "Zhen Zhang and Xianlan Zhao and Tengfei Zhang and Liping Wang and Lingzhu Yang and Lan Huang and Feng Li and Jinyan Liu and Dongli Yue and Fei Wang and Jieyao Li and Fangxia Guan and Yuming Xu and Bin Zhang and Yi Zhang",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.jcyt.2014.09.006",
language = "English (US)",
volume = "17",
pages = "86--97",
journal = "Cytotherapy",
issn = "1465-3249",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Phenotypic characterization and anti-tumor effects of cytokine-induced killer cells derived from cord blood

AU - Zhang, Zhen

AU - Zhao, Xianlan

AU - Zhang, Tengfei

AU - Wang, Liping

AU - Yang, Lingzhu

AU - Huang, Lan

AU - Li, Feng

AU - Liu, Jinyan

AU - Yue, Dongli

AU - Wang, Fei

AU - Li, Jieyao

AU - Guan, Fangxia

AU - Xu, Yuming

AU - Zhang, Bin

AU - Zhang, Yi

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background aims: Cytokine-induced killer (CIK) cell therapy represents a feasible immunotherapeutic option for treating malignancies. However, the number of anti-tumor lymphocytes cannot be easily obtained from the cancer patients with poor immunity status, and older patients cannot tolerate repeated collection of blood. Cord blood-derived CIK (CB-CIK) cells have shown efficacy in treating the patients with cancer in several clinical trials. This study was conducted to evaluate the biological characteristics and anti-tumor function of CB-CIK cells. Methods: The immunogenicity, chemokine receptors and proliferation of CB-CIK cells were analyzed by flow cytometry. The CIK cells on day 13 were treated with cisplatin and the anti-apoptosis capacity was analyzed. The function of CB-CIK cells against the human cancer was evaluated both in vitro and in vivo. Results: Compared with peripheral blood-derived CIK (PB-CIK) cells, CB-CIK cells demonstrated lower immunogenicity and increased proliferation rates. CB-CIK cells also had a higher percentage of main functional fraction CD3+CD56+. The anti-apoptosis ability of CB-CIK cells after treatment with cisplatin was higher than that of PB-CIK cells. Furthermore, CB-CIK cells were effective for secreting interleukin-2 and interferon-γ and a higher percentage of chemokine receptors CCR6 and CCR7. In addition, tumor growth was greatly inhibited by CB-CIK treatment in a nude mouse xenograft model. Conclusions: CB-CIK cells exhibit more efficient anti-tumor activity in in vitro analysis and in the preclinical model and may serve as a potential therapeutic approach for the treatment of cancer.

AB - Background aims: Cytokine-induced killer (CIK) cell therapy represents a feasible immunotherapeutic option for treating malignancies. However, the number of anti-tumor lymphocytes cannot be easily obtained from the cancer patients with poor immunity status, and older patients cannot tolerate repeated collection of blood. Cord blood-derived CIK (CB-CIK) cells have shown efficacy in treating the patients with cancer in several clinical trials. This study was conducted to evaluate the biological characteristics and anti-tumor function of CB-CIK cells. Methods: The immunogenicity, chemokine receptors and proliferation of CB-CIK cells were analyzed by flow cytometry. The CIK cells on day 13 were treated with cisplatin and the anti-apoptosis capacity was analyzed. The function of CB-CIK cells against the human cancer was evaluated both in vitro and in vivo. Results: Compared with peripheral blood-derived CIK (PB-CIK) cells, CB-CIK cells demonstrated lower immunogenicity and increased proliferation rates. CB-CIK cells also had a higher percentage of main functional fraction CD3+CD56+. The anti-apoptosis ability of CB-CIK cells after treatment with cisplatin was higher than that of PB-CIK cells. Furthermore, CB-CIK cells were effective for secreting interleukin-2 and interferon-γ and a higher percentage of chemokine receptors CCR6 and CCR7. In addition, tumor growth was greatly inhibited by CB-CIK treatment in a nude mouse xenograft model. Conclusions: CB-CIK cells exhibit more efficient anti-tumor activity in in vitro analysis and in the preclinical model and may serve as a potential therapeutic approach for the treatment of cancer.

KW - Cancer

KW - Cord blood

KW - Cytokine-induced killer cells

KW - Peripheral blood

UR - http://www.scopus.com/inward/record.url?scp=84927125715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927125715&partnerID=8YFLogxK

U2 - 10.1016/j.jcyt.2014.09.006

DO - 10.1016/j.jcyt.2014.09.006

M3 - Article

C2 - 25457278

AN - SCOPUS:84927125715

VL - 17

SP - 86

EP - 97

JO - Cytotherapy

JF - Cytotherapy

SN - 1465-3249

IS - 1

ER -